Loading...
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
During the last 10 years, the multikinase inhibitor sorafenib has emerged as the only systemic treatment for unresectable hepatocellular carcinoma (HCC). More recently, data from the Phase III REFLECT trial showed that another multikinase inhibitor, namely, lenvatinib, was non-inferior to sorafenib...
Na minha lista:
| Udgivet i: | J Hepatocell Carcinoma |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6362912/ https://ncbi.nlm.nih.gov/pubmed/30775342 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S168953 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|